Stockreport

Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder

UROVANT SCIENCES LTD COMMON  (UROV) 
Last urovant sciences ltd common earnings: 2/13 04:15 pm Check Earnings Report
PDF IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing an [Read more]